Paper Poster Presentations
At the ESCMID/ASM conference selected paper posters will be shown during two dedicated poster sessions:
- Wednesday, 5 October 2022: 17:00 - 18:30
- Thursday, 6 October 2022: 17:15 - 18:15
During these sessions the presenting author will be standing next to their poster and lively discussions are encouraged. Refreshments and snacks will be offered, while the sessions are taking place, for the presenters and attendees.
Top 10 selected posters will be presented orally during Top Poster Presentations session on Friday, 7 October between 12:00 and 13:40.
List of posters selected for oral presentation:
- EA42 - Antibody-antibiotic conjugate for melioidosis – Adam Taylor
- EA70 - Improving the accuracy of in vitro antimicrobial testing with simulated body fluid – Connagh Redmond
- EA13 - Identifying the network of bactericidal interactions between mycobacterial respiratory chain complexes to develop fast-acting drugs for tuberculosis – Greg Cook
- EA28 - In vivo potency of a novel class of outer membrane protein targeting antibiotic (OMPTA) that disassemble the lipopolysaccharide transport bridge (LptA) – Françoise Jung
- EA15 - Inter-species interactions alter antimicrobial susceptibility in polymicrobial cultures - Eva Bernadett Benyei
- EA09 - Participant, geographic, and surgical factors are associated with clinical failure in registrational trials for complicated intraabdominal infection – Tori Kinamon
- EA19 - Characterisation of novel, non-covalent cyclic peptide (Bicycles®) inhibitors of PBP3s from important Gram-negative pathogens – Hector Newman
- EA49 - The bacterial itaconate degradation pathway: an immune system evasion mechanism and antimicrobial target – Jacob Pierscianowski
- EA01 - Time to change the complicated urinary tract infection primary endpoint? The problem and a potential solution – Paul McGovern
- EA37 - Monoclonal antibodies against BauA and OmpW2 disrupt growth, prevent sepsis, and promote survival of mice infected with Acinetobacter baumannii – Daniel Zurawski
Poster instructions can be found below on this page.
The list of all accepted abstracts can be found below:
Abstract number | Abstract title | Presenter |
---|---|---|
EA01 | Time to change the complicated urinary tract infection primary endpoint? The problem and a potential solution | Paul McGovern |
EA02 | Population pharmacokinetics of apramycin to support prediction of efficacious dose with first-in-human trial data | Anna Chirkova |
Abstract number | Abstract title | Presenter |
---|---|---|
EA03 | Cefepime-taniborbactam and comparator activity in vitro against carbapenem-resistant Enterobacterales (CRE), carbapenem-resistant Pseudomonas aeruginosa (CRPA) and multidrug-resistant (MDR) Enterobacterales and P. aeruginosa from 2018-2020 surveillance | Greg Moeck |
EA04 | Biological evaluation of novel phosphonate inhibitors targeting Pseudomonas aeruginosa elastase LasB | Roya Shafiei |
EA05 | Octapeptins - independent antibiotic agents or antibiotic adjuvants to treat MDR/PmxR Gram-negative bacteria? | Johannes Zuegg |
EA06 | Developing a novel antimicrobial-phytochemical conjugate with antimicrobial activity against Streptococcus uberis, Enterococcus faecium and Enterococcus faecalis | Jian Yang |
EA07 | A study of restoring tobramycin effectiveness toward resistant Gram-negative bacteria by encapsulate it in liposomal formulation containing methylglyoxal (Lip-MGO-TOB) | Wed Alluhaim |
EA08 | DNV3837, a parenteral GI tract-targeted treatment for Clostridioides difficile infection | Georges Gaudriault |
EA09 | Participant, geographic, and surgical factors are associated with clinical failure in registrational trials for complicated intraabdominal infection | Tori Kinamon |
EA10 | BARDA’s Investments and priorities in product development to combat antimicrobial resistance | Jessica Swenson |
EA12 | Novel dual bacterial topoisomerases inhibitors with broad-spectrum antibacterial activity | Martina Hrast |
Abstract number | Abstract title | Presenter |
---|---|---|
EA13 | Identifying the network of bactericidal interactions between mycobacterial respiratory chain complexes to develop fast-acting drugs for tuberculosis | Greg Cook |
EA14 | Towards the discovery of new DDl inhibitors using a fragment-based drug discovery | Rok Frlan |
EA15 | Inter-species interactions alter antimicrobial susceptibility in polymicrobial cultures | Eva Bernadett Benyei |
EA17 | Penicillin binding protein inhibitors of EcPBP3 discovered using a modified phage display platform (Bicycles®) | Nikolaos Bournakas |
EA18 | Chemical-chemical interaction profiling reveals a Rod complex inhibitor | Rinki Gupta |
EA19 | Characterisation of novel, non-covalent cyclic peptide (Bicycles®) inhibitors of PBP3s from important Gram-negative pathogens | Hector Newman |
EA20 | RECCE® 327 demonstrates bactericidal activity against several microbial species | Philip Sutton |
EA21 | Antibacterial, safety, efficacy and molecular mechanism-of-action of halogenated codonopsinine derivative (HCD1) against methicillin-resistant Staphylococcus aureus (MRSA) | Saiful Azmi Johari |
EA22 | Organic derivatives of silichristin elicited potent antibacterial activity against penicillin-binding protein 3 of Pseudomonas aeruginosa in silico | Jamiu Aribisala |
EA23 | Design of small-molecule drugs to target multiple bacterial tRNA synthetases | Lorenzo Pavanello |
EA24 | WGS-based dual strategy for the Identification of key targets to enhance beta-lactam activity in Mycobacterium tuberculosis | Francisco Olivença |
EA25 | Discovery of PK-188 as novel non-competitive inhibitor targeting NDM-1 and VIM metallo-β-lactamases | Vidmantas Petraitis |
Abstract number | Abstract title | Presenter |
---|---|---|
EA26 | Fragment class with carbapenemase inhibition and antibacterial activity | Hannelore Meyer |
EA27 | In vitro potency and selectivity of a novel class of outer membrane protein targeting antibiotics (OMPTA) that disassemble the lipopolysaccharide transport bridge (LptA) | Carolin D'Arco |
EA28 | In vivo potency of a novel class of outer membrane protein targeting antibiotic (OMPTA) that disassemble the lipopolysaccharide transport bridge (LptA) | Françoise Jung |
EA29 | In vitro bactericidal activity of NOSO 502: a novel action odilorhabdin antibiotic | Alasdair MacGowan |
EA30 | Antibacterial interactions of NOSO-502 studied by checkerboard method using combinations with amikacin, ciprofloxacin, colistin, meropenem and tigecycline against Enterobacterales | Alasdair MacGowan |
EA31 | Antimicrobial activity of ceftolozane/tazobactam and imipenem/relebactam in Dutch Pseudomonas aeruginosa isolates obtained from patients at the ICU, Pulmonology and Urology Depts. collected during 10 years of surveillance | Peter Croughs |
EA32 | Metallobiotics: A new class of antimicrobial agents? | Mark Blaskovich |
EA33 | Conjugated oligoelectrolytes – a novel antibiotic platform with activity against nontuberculous mycobacteria | Kaixi Zhang |
Abstract number | Abstract title | Presenter |
---|---|---|
EA35 | Recurring problems and mitigation strategies in the development of monoclonal antibodies against AMR pathogens: a report from the COMBINE Expert Workshop | Linda Marchioro |
EA36 | Lysins as promising antibacterial therapeutics against uropathogenic Escherichia coli | Syed Ahmed |
EA37 | Monoclonal antibodies against BauA and OmpW2 disrupt growth, prevent sepsis, and promote survival of mice infected with Acinetobacter baumannii | Daniel Zurawski |
EA39 | Cannabidiol (CBD) as novel non-traditional antimicrobial candidate targeting methicillin-resistant and vancomycin-intermediate Staphylococcus aureus | Vidmantas Petraitis |
Abstract number | Abstract title | Presenter |
---|---|---|
EA40 | P. aeruginosa grown in printable cystic fibrosis model biofilms suitable for high-throughput screening of antibiotics interactions | Goodness Ogechi Osondu-Chuka |
EA41 | Antisense based anti-adhesive strategy against bacterial urinary tract infection | Elnaz Harifi Mood |
EA42 | Antibody-antibiotic conjugate for melioidosis | Adam Taylor |
EA43 | Polymersome encapsulation to enhance antibiotic delivery for the treatment of melioidosis | Kimberley Wright |
EA44 | Romo1-derived antimicrobial peptide is a new antimicrobial agent against multidrug-resistant bacteria in a murine model of sepsis | Young Do Yoo |
EA45 | Pharmacodynamics of bacterial efflux pump inhibitors (EPI): proof of concept studies | Alasdair MacGowan |
EA46 | Activity of the novel engineered antimicrobial peptide PLG0206 against non-fermenting Gram-negative rods | Ian Morrissey |
EA47 | Organoselenium inhibitors reduce ureolysis and viability of C. neoformans and H. pylori | Agnieszka Grabowiecka |
EA48 | Ebselen derivatives as picomolar inhibitors of bacterial ureases | Wojciech Tabor |
EA49 | The bacterial itaconate degradation pathway: an immune system evasion mechanism and antimicrobial target | Jacob Pierscianowski |
EA50 | A novel, clinically relevant polymyxin, SPR206, eradicates all Gram-negatives associated with wound infection and prevents infection in vivo | Daniel Zurawski |
EA51 | Using guided antimicrobial peptides to modulate antimicrobial resistance patterns in Helicobacter pylori | Patrick Ortiz |
EA52 | In vitro efficacy and pharmacodynamics of novel 1,10-phenanthroline-5,6-dione-based metal compounds against Acinetobacter baumannii MDR clinical strains | Ingrid Peregrino |
EA53 | Efficacy of cefiderocol in experimental Stenotrophomonas maltophilia pneumonia in persistently neutropenic rabbits | Vidmantas Petraitis |
EA54 | The combination therapy with polymyxin B nonapeptide eradicates persisters | Jihyeon Kim |
Abstract number | Abstract title | Presenter |
---|---|---|
EA56 | Rapid endpoint method for the quantification of Mycobacterium tuberculosis (Mtb) subjected to three different treatment regimens within the hollow fibre system (HFS) | Stephanie Sandiford |
EA57 | Pharmacodynamics of WCK 4282 (high dose cefepime plus tazobactam) against βlactamase producing E. coli | Alasdair MacGowan |
EA58 | Newly synthesized 5-pyrazolyl substituted 2,4-thiazolidinedione as potential anti-inflammatory and antimicrobial agent | Yulian Konechnyi |
EA59 | Preclinical development of CRS0393 as a novel antimycobacterial agent that inhibits MmpL3 | Urs Ochsner |
EA60 | A standard protocol for the murine pneumonia model to evaluate treatments for AMR lung infections | Jon Ulf Hansen |
EA61 | In vivo pharmacodynamic evaluation of meropenem-nacubactam in murine thigh and lung infection models against Klebsiella pneumoniae (KPN) containing OXA-48-like enzymes | Alexander Lepak |
EA62 | In vivo pharmacodynamic evaluation of CRS0540 in the murine thigh and lung infection models against Staphylococcus aureus | Alexander Lepak |
EA63 | Preclinical evaluation of apramycin as a drug candidate for Mycobacterium abscessus infections | Sven Hobbie |
EA64 | Novel bacterial topoisomerase inhibitor gepotidacin demonstrates absence of fluoroquinolone-like arthropathy in juvenile rats | Cindy Fishman |
EA64A | Murine vaginal infection models with MDR Neisseria gonorrhoeae isolates for pharmacology studies | Lynn Miesel |
Abstract number | Abstract title | Presenter |
---|---|---|
EA66 | Sticker reminder for IV-to-PO switching of fluoroquinolone therapy; preliminary results of a cluster-randomized controlled trial | Pinyo Rattanaumpawan |
EA69 | Real-world analysis of new antibiotic use at a US medical center with multi-drug resistant (MDR) Pseudomonas aeruginosa (PSA) but a paucity of carbapenemase-producing Enterobacterales (CPE) | Alexander Lepak |
EA69A | Antimicrobial Stewardship in the management of bloodstream infections caused by AmpC-producing Enterobacterales | Elaine Houlihan |
Abstract number | Abstract title | Presenter |
---|---|---|
EA70 | Improving the accuracy of in vitro antimicrobial testing with simulated body fluid | Connagh Redmond |
EA71 | BPO: the Bioassay Protocol Ontology, a semantic approach to elevate the reusability of AMR-related drug discovery data | Rakel Arrazuria |
EA73 | Correlation between antimicrobial resistance and immune-depression in pediatrics: a retrospective study from the Bambino Gesù Children Hospital of Rome | Danielle Domo |
EA74 | Cd resistance leads antibiotic resistance in bacteria of host and non-host environment | Juoae Chang |
Poster Instructions
Size
A1 Portrait
A1 size is 841 x 594mm - ( 33.1 x 23.4 inches )
Please make sure to put your poster number on your poster!
- Posters will be adjusted with provided pins
- Self adhesive circles will be provided and can be attached to the rear of the posters.
- The material of the boards is Velcro and with the needles all kinds of poster materials can be attached

Printing options
ESCMID is not working with an official provider, however here are some suggestions from the convention bureau:
Snap Printing:https://www.snap.ie/contact-a-centre/snap-blanchardstown/ (taxi drive away)
Hadleighprint:http://www.hadleighprint.ie/_delivery/delivery.aspx (30 second drive or 25 minute walk)
Mullen Print:http://www.mullenprint.com/ (taxi drive away)
For questions, please email conferences[at]escmid.org